$50,000 of TAKEDA PHARMACEUTICALS AMERICA INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to Plasma-Derived Therapies; Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to National Priority Voucher (CNPV) program."
You can find more data on corporate lobbying on Quiver Quantitative.
TAK Hedge Fund Activity
We have seen 163 institutional investors add shares of TAK stock to their portfolio, and 158 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 4,012,456 shares (+1426.4%) to their portfolio in Q4 2025, for an estimated $62,554,189
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 2,854,069 shares (+100.9%) to their portfolio in Q4 2025, for an estimated $44,494,935
- TORONTO DOMINION BANK removed 2,181,100 shares (-72.6%) from their portfolio in Q4 2025, for an estimated $34,003,349
- UBS GROUP AG removed 1,770,446 shares (-30.0%) from their portfolio in Q4 2025, for an estimated $27,601,253
- MILLENNIUM MANAGEMENT LLC removed 1,666,117 shares (-65.2%) from their portfolio in Q4 2025, for an estimated $25,974,764
- QUBE RESEARCH & TECHNOLOGIES LTD removed 1,578,338 shares (-88.9%) from their portfolio in Q4 2025, for an estimated $24,606,289
- MORGAN STANLEY removed 1,317,213 shares (-17.1%) from their portfolio in Q4 2025, for an estimated $20,535,350
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
